Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

IRLAB Aktie

>IRLAB Performance
1 Woche: -10,9%
1 Monat: -20,7%
3 Monate: -28,4%
6 Monate: -44,5%
1 Jahr: -82,6%
laufendes Jahr: -28,4%
>IRLAB Aktie
Name:  IRLAB THERAP. AB A
Land:  Schweden
Sektor:  Gesundheit
ISIN/ Wkn:  SE0012675361 / A2PLBE
Symbol/ Ticker:  6IRA (Frankfurt)
Kürzel:  FRA:6IRA, ETR:6IRA, 6IRA:GR
Index:  -
Webseite:  https://www.irlab.se/
Profil:  Irlab Therapeutics AB, a prominent biotechnology company, focuses on developing transformative therapies for central nervous system (CNS) disorders. Positioned at the cutting edge of pharmaceutical innovation, the company dedicates its efforts to res..
>Volltext..
Marktkapitalisierung:  11.15 Mio. EUR
Unternehmenswert:  6.39 Mio. EUR
Umsatz:  5.39 Mio. EUR
EBITDA:  -8.25 Mio. EUR
Nettogewinn:  -10.31 Mio. EUR
Gewinn je Aktie:  -0.17 EUR
Schulden:  2.81 Mio. EUR
Liquide Mittel:  7.67 Mio. EUR
Operativer Cashflow:  -5.18 Mio. EUR
Bargeldquote:  0.76
Umsatzwachstum:  -39.28%
Gewinnwachstum:  -32.34%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  IRLAB
Letzte Datenerhebung:  05.04.26
>IRLAB Kennzahlen
Aktien/ Unternehmen:
Aktien: 84.86 Mio. St.
Frei handelbar: 94.03%
Leerverk. Aktien: -
Rückkaufquote: -62.69%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: No rating
Kursziel: 425.95%
Bewertung:
KGV: -
KGV lG: -
KUV: 2.04
KBV: 3.94
PEG-Ratio: -0.05
EV/EBITDA: -
Rentabilität:
Bruttomarge: -160.71%
Gewinnmarge: -191.45%
Operative Marge: -160.71%
Managementeffizenz:
Gesamtkaprendite: -80.18%
Eigenkaprendite: -347.29%
>IRLAB Peer Group
Gesundheit, Parkinson- Behandlung, Neurologische- & psychische Behandlung/ Medizin
 
17.03.26 - 09:06
IRLAB Therapeutics: IRLAB to Present Clinical and Preclinical Data at The AD/PD 2026 - 20th International Conference on Alzheimer′s & Parkinson′s Diseases (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / March 17, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced tha......
02.03.26 - 09:18
IRLAB Therapeutics: IRLAB Participates in Life Science Day in Gothenburg on March 4, 2026 (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / March 2, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that th......
26.02.26 - 12:30
IRLAB Therapeutics: IRLAB Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson′s Disease (Accesswire)
 
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, NE / ACCESS Newswire / February 26, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA)......
25.02.26 - 07:30
IRLAB Therapeutics: IRLAB Publishes Full-Year Report for The Period January - December 2025 (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / February 25, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced ......
20.02.26 - 07:30
IRLAB Therapeutics: IRLAB has Received Scientific Advisory Board Confirmation on Next Steps for Pirepemat (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / February 20, 2026 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced tha......
18.02.26 - 07:27
IRLAB Therapeutics: IRLAB: Invitation to the Year-End Report 2025 Presentation and Webcast (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / February 18, 2026 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's......
19.01.26 - 12:06
IRLAB Therapeutics: IRLAB Enters Collaboration Agreement with Danish Biotech Company Biomia ApS Applying the Integrative Screening Process (Accesswire)
 
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, SE / ACCESS Newswire / January 19, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA),......
23.12.25 - 08:06
IRLAB Therapeutics: IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson′s Disease (Accesswire)
 
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, NE / ACCESS Newswire / December 23, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm: IRLA......
11.12.25 - 07:30
IRLAB Therapeutics: The European Patent Office Intends to Grant a New Patent for IRLAB′s Mesdopetam (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / December 11, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's......
27.11.25 - 07:42
IRLAB Therapeutics: IRLAB Participates in Redeye Technology & Life Science Day on December 3, 2025 (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / November 27, 2025 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced ......
20.11.25 - 17:06
IRLAB Therapeutics: Nomination Committee Appointed for IRLAB′s Annual General Meeting 2026 (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / November 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announces tha......
07.11.25 - 07:33
IRLAB Therapeutics: IRLAB Receives Acceptance for Two Abstracts at AD/PD 2026: The 20th International Conference on Alzheimer′s and Parkinson′s Diseases (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / November 7, 2025 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced t......
29.10.25 - 07:30
IRLAB Therapeutics: IRLAB Publishes Interim Report for The Period January - September 2025 (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / October 29, 2025 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced t......
23.10.25 - 07:30
IRLAB Therapeutics: IRLAB: Invitation To The Interim Report For Q3 2025 Presentation And Webcast (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / October 23, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's......
09.10.25 - 17:42
IRLAB Therapeutics: IRLAB Appoints Gustaf Albèrt as the New Chief Financial Officer (Accesswire)
 
GOTHENBURG, SWEDEN / ACCESS Newswire / October 9, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced t......
09.10.25 - 07:31
IRLAB Therapeutics: IRLAB to Present at Redeye Theme: Neurology (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / October 9, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treat......
02.10.25 - 07:31
IRLAB Therapeutics: IRLAB Progresses Fully Funded IRL757 Study in Parkinson′s Disease in Partnership with MSRD (Accesswire)
 
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, SE / ACCESS Newswire / October 2, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - Go......
04.09.25 - 07:30
IRLAB Therapeutics: IRLAB Is Granted a Patent Strengthening the Market Exclusivity of The Drug Candidate Mesdopetam in China (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / September 4, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announc......
02.09.25 - 11:18
PulPac appoints Viktor Siewertz as Chief Financial Officer (Cision)
 
PulPac, the Swedish innovation company behind Dry Molded Fiber, today announces the appointment of Viktor Siewertz as Chief Financial Officer (CFO), effective September 1, 2025. [image] Viktor Siewertz, newly appointed CFO at PulPac Viktor Siewertz joins PulPac from IRLAB Therapeutics AB, listed on Nasdaq Stockholm Main Market, where he has served as CFO since 2017. With over 25 years of experience in finance, law, and corporate governance, he brings extensive expertise in accounting, capital markets, financial strategy, and investor relations. During his tenure at IRLAB, Siewertz...
29.08.25 - 07:30
Change in Number of Shares and Votes in IRLAB Therapeutics AB (Accesswire)
 
GOTHENBURG, SE / ACCESS Newswire / August 29, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) - During August 2025, the registered number of shares and votes in IRLAB Therapeutics AB ("IRLAB") ha......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!